tbuckley/cabot-search huggingface dataset:
Autoimmune disease in dermatitis herpetiformis
Authors: J.P. McFadden, J.N. Leonard, A.V. Powles, A.J. Rutman, L. Fry
Journal: British Journal of Dermatology (1989)

Journal Article Autoimmune disease in dermatitis herpetiformis Get access J.P. McFadden, J.P. McFadden St. Mary's Hospital, London Search for other works by this author on: Oxford Academic Google Scholar J.N. Leonard, J.N. Leonard St. Mary's Hospital, London Search for other works by this author on: Oxford Academic Google Scholar A.V. Powles, A.V. Powles St. Mary's Hospital, London Search for other works by this author on: Oxford Academic Google Scholar A.J. Rutman, A.J. Rutman St. Mary's Hospital, London Search for other works by this author on: Oxford Academic Google Scholar L. Fry L. Fry St. Mary's Hospital, London Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 121, Issue s34, 1 July 1989, Pages 48–49, https://doi.org/10.1111/j.1365-2133.1989.tb05949.x Published: 01 July 1989
Case 26-1986
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Martin A. Samuels, E. Tessa Hedley-Whyte, Robert H. Brown
Journal: New England Journal of Medicine (1986)

Presentation of CaseA 62-year-old man was admitted to the hospital because of progressive polyneuropathy.The patient was well until two or three years earlier, when he began to experience burning sensations in the soles of his feet, with numbness of the feet and ankles. Several months later a feeling of pins and needles developed in all his fingers. Electromyographic studies, performed elsewhere, were reported to show abnormalities. Twenty-three months before entry surgical release of the right carpal tunnel was performed, without improvement; four months later the region of the right elbow was explored, again without benefit. By this time . . .
The Metabolic Regulation and Vesicular Transport of GLUT4, the Major Insulin-Responsive Glucose Transporter*
Authors: JACQUELINE M. STEPHENS, PAUL F PILCH
Journal: Endocrine Reviews (1995)

GLUCOSE is the primary energy source for the brain under normal physiological circumstances and is acutely taken up by other mammalian cells for immediate use as metabolic energy or for storage as glycogen in liver and muscle. It also serves as a precursor to a variety of metabolites in many, if not all, tissues. Glucose is released into circulation from the liver in the fasting state as a result of glycogen breakdown and is used (oxidized) for the energetic needs of contraction in skeletal muscle. The entry of glucose into the blood is a function of the nutritional state of the mammalian organism, and the postprandial clearance of glucose from the circulation is tightly regulated by insulin. The mechanism of this regulation is the focus of this review. Since the cell membrane is impermeable to glucose, it is transported by specific carrier proteins or transporters that span the cell membrane and allow the binding and transfer of glucose across the hydrophobic lipid bilayer. Two general classes of glucose carriers have been described in mammalian cells: 1) the energy-dependent Na+/glucose cotransporter, which can concentrate glucose against a gradient, and 2) the facilitative glucose transporters, which work in the direction of the glucose gradient. The physiological function of the Na+/glucose cotransporter takes place in polarized epithelial cells where it transports glucose from the lumen of the intestine into the cell (1, 2). The subsequent facilitative transport of glucose out of the intestinal epithelium allows entry of glucose into the blood. The Na+/glucose cotransporter is also expressed in the kidney where it serves to retain glucose and prevent its spillage into urine. The entry of glucose into different tissues via facilitative glucose carriers must serve different physiological needs in these different tissues; these needs are met by a family of related transporter proteins, expressed in a tissue-specific manner, whose biochemical properties serve the appropriate physiological needs of the organism. These six proteins (and one pseudogene) are called GLUTs for glucose transporters. The focus of this review is GLUT4, the expression of which is limited to the major insulin target tissues of fat and cardiac and skeletal muscle where it serves as the major mediator of glucose uptake that responds to the hormone.
Anabolic steroids and psoriasis exacerbation
Authors: J.T. Lear, J.S.C. English
Journal: British Journal of Dermatology (1996)

Journal Article Anabolic steroids and psoriasis exacerbation Get access J.T. Lear, J.T. Lear Department of Dermatology, North Staffs Hospital Ceittre, Newcastle Road, Stoke on Trent, ST4 7PA, U.K. Search for other works by this author on: Oxford Academic Google Scholar J.S.C. English J.S.C. English Department of Dermatology, North Staffs Hospital Ceittre, Newcastle Road, Stoke on Trent, ST4 7PA, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 134, Issue 4, 1 April 1996, Page 809, https://doi.org/10.1111/j.1365-2133.1996.tb07000.x Published: 01 April 1996
Research consortium highlights importance of taking part in trials
Authors: Roger Dobson
Journal: BMJ (2007)

A new information booklet for patients has been produced that emphasises the advantages of taking part in clinical trials and the safety precautions that are taken.

Launched by the UK Clinical Research Collaboration, the booklet—together with an accompanying leaflet—also recommends the questions to which patients should seek answers when considering taking part in trials, and it describes the label “guinea pig” as misleading.

“Clinical trials are the best way to compare different approaches to preventing and treating illness and health problems. Without trials, there is a risk that people could be given treatments which have no advantage, waste resources and might even …
Temporal National Trends of Minimally Invasive and Retropubic Radical Prostatectomy Outcomes from 2003 to 2007: Results from the 100% Medicare Sample
Authors: Keith J. Kowalczyk, Jesse M. Levy, Craig F. Caplan, Stuart R. Lipsitz, Hua-yin Yu, Xiangmei Gu, Jim C. Hu
Journal: European Urology (2011)
Binding of diamine oxidase activity to rat and guinea pig microvascular endothelial cells. Comparisons with lipoprotein lipase binding.
Authors: A Robinson-White, S B Baylin, T Olivecrona, M A Beaven
Journal: Journal of Clinical Investigation (1985)

Microvascular endothelial cells from rat and guinea pig fat pads were shown to bind diamine oxidase (DAO) activity when incubated with soluble extracts of placenta (33 DAO U/mg of placenta) and a purified placental enzyme preparation (94 U/micrograms of protein). The extent of binding was dependent on the concentration of enzyme activity and tissue. Saturation of binding sites with 5,000 U of DAO/ml resulted in levels of bound activity (up to 11-13 U/mg of endothelial cells) in excess of that observed in all tissues except placenta. Scatchard plots suggested that there were at least two DAO binding sites (apparent Km 92 and 2,450 U/ml). Although the same cell preparations bound 125I-labeled lipoprotein lipase (LPL), the presence of LPL on the endothelial cell surface did not interfere with the binding of DAO activity except when cells were exposed to high concentrations of LPL. Alternatively, bound DAO activity was partially displaced (up to 33%) only with high concentrations (30 micrograms/ml) of LPL. DAO activity may thus be bound to at least two populations of sites, one of which may bind LPL. Both enzymes, however, were displaced by heparin (0.05-5 U/ml) and DAO binding was impaired by prior treatment of cells with proteolytic and glycosaminoglycandegrading enzymes. The demonstration of DAO binding to vascular endothelial cells provides a further example of the ability of these cells to bind enzymes at their surface and thereby act on biologically active substances in the circulation.
The role of symptomatic colds in asthma exacerbations: Influence of outdoor allergens and air pollutants☆
Authors: Susan M. Tarlo, Irvin Broder, Paul Corey, Moira Chan-Yeung, Alexander Ferguson, Allan Becker, Christine Rogers, Marilyn Okada, Jure Manfreda
Journal: Journal of Allergy and Clinical Immunology (2001)
Gynaecomastia and Testicular Aplasia
Authors: D. Ferriman
Journal: BMJ (1950)

SCLEROSISRICJRA to disseminated sclerosis, with the following secondary causes No. of Cases Disease of the urinary system (with subsequent toxic absorption or uraemia) .12(21 1%) Disease of the respiratory system (bronchopneumonia, 15; basal pneumonia, 2; pleurisy, 1; pulmonary embolism, 1; empyema, 2; lung abscess, I; tuber- culosis, 4) 26 (45.5%)Carcinoma .2(3-5%) Perforated peptic ulcer .1 (1 8%.)Death during laminectomy .3(5 3%) Cerebral haemorrhage .1 (1-8%)Overdose of a hypnotic .1 (1-8%)Aplastic anaemia from arsenical treatment 1 (1-8%) Disseminated sclerosis involving the medulla 2 (3 5%) No immediate cause (death ascribed to cachexia7and
Egypt tightens ban on female genital mutilation after 12 year old girl dies
Authors: Mimet Meleigy
Journal: BMJ (2007)

Egypt has announced that it is imposing a complete ban on female genital mutilation. The ban was imposed last week by the Ministry of Health after a public outcry over the death of a 12 year old girl, Budour Ahmad Shaker, who died from an overdose of anaesthetic while being circumcised.

After the much publicised death of the girl, the Egyptian Center for Women's Rights appealed to the government for a law that would criminalise the practice and that would “punish doctors who commit this crime, and close clinics and hospital that continue to practise it.” The doctor who had carried out the circumcision on the girl has been arrested, and the clinic where it took place has been closed down.

In Egypt 75% of female genital mutilation is carried out by doctors and nurses, and 25% are carried out by birth attendants, or …
Glutathione <i>S</i>-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy
Authors: Thierry Lecomte, Bruno Landi, Philippe Beaune, Pierre Laurent-Puig, Marie-Anne Loriot
Journal: Clinical Cancer Research (2006)

Abstract Purpose: Glutathione S-transferases (GST) are xenobiotic metabolizing enzymes involved in the detoxification of a variety of chemotherapeutic drugs, including platinum derivatives. Genetic polymorphisms of GSTs have been associated with enzyme activity variations. Thus, a study was done to investigate the relationship between GST polymorphisms and oxaliplatin-related cumulative neuropathy in gastrointestinal cancer patients treated with oxaliplatin-based chemotherapy. Experimental Design: Ninety patients were included. Clinical neurologic evaluation was done at baseline and before each cycle of treatment. We determined genetic variants for GSTP1 exon 5 (Ile105Val), GSTP1 exon 6 (Ala114Val), GSTM1 (homozygous deletion), and GSTT1 (homozygous deletion). We conducted analyses in a subgroup of 64 patients receiving a minimal cumulative dose of 500 mg/m2 of oxaliplatin to examine whether the GST polymorphisms are associated with oxaliplatin-related cumulative neuropathy. Results: Among patients receiving a minimal cumulative dose of 500 mg/m2 of oxaliplatin, 15 patients showed clinically evident oxaliplatin-related cumulative neuropathy scored grade 3 according to an oxaliplatin-specific scale. The oxaliplatin-related cumulative neuropathy scored grade 3 was significantly more frequent in patients homozygous for the GSTP1 105Ile allele than in patients homozygous or heterozygous for the GSTP1 105Val allele (odds ratio, 5.75; 95% confidence interval, 1.08-30.74; P = 0.02). No association was found with respect to any of the GSTM1, GSTT1, or GSTP1 exon 6 genotypes. Conclusions: The results of the current study suggest that the 105Val allele variant of the GSTP1 gene at exon 5 confers a significantly decreased risk of developing severe oxaliplatin-related cumulative neuropathy.
P757 REDUCING POLYMORPHISMS CONSISTING OF (TA)N DINUCLEOTIDE REPEAT NEAR IL28B GENE ASSOCIATE WITH THE DEVIATION OF IL28B SNPS AND AFFECT VIRAL RESPONSE OF PEGIFN/RBV
Authors: M. Korenaga, M. Sugiyama, T. Takeda, Y. Aoki, S. Yoshio, Y. Yamagiwa, K. Korenaga, N. Nishida, K. Murata, T. Kanto, N. Masaki, M. Mizokami, M. Imamura
Journal: Journal of Hepatology (2014)
IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells
Authors: Mark A. Brockman, Douglas S. Kwon, Daniel P. Tighe, David F. Pavlik, Pamela C. Rosato, Jennifer Sela, Filippos Porichis, Sylvie Le Gall, Michael T. Waring, Kristin Moss, Heiko Jessen, Florencia Pereyra, Daniel G. Kavanagh, Bruce D. Walker, Daniel E. Kaufmann
Journal: Blood (2009)
Patent Ductus Arteriosus and Loss of Hearing
Authors: HELEN B. TAUSSIG
Journal: Annals of Internal Medicine (1968)

Editorial Notes1 July 1968Patent Ductus Arteriosus and Loss of HearingHELEN B. TAUSSIG, M.D.HELEN B. TAUSSIG, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-69-1-167 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn an investigation of patent ductus arteriosus and loss of hearing, Dahl and Boesen (1) studied the acuity of hearing in 99 patients with a patent ductus arteriosus as an isolated malformation. Audiometer tests were considered indicative of hearing loss, if a 40 or more decibel loss occurred in at least three frequencies. Bone conduction was not investigated, and no studies were undertaken to determine the nature of the loss of hearing. Nevertheless, 9 of the 99 children were found to have a hearing loss. The mothers of three of the nine children gave a history of rubella during the...Reference1. DAHLBOESEN GI: Patent ductus arteriosus and loss of hearing. Danish Med. Bull. 15: 6, 1968. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Johns Hopkins University Baltimore, Md. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe reaction of sulfamic acid derivatives with epoxidesHelen brooke taussig: 1898 to 1986 1 July 1968Volume 69, Issue 1Page: 167-167KeywordsBoneChildrenHearingPatent ductus arteriosusRubella Issue Published: 1 July 1968 PDF DownloadLoading ...
INSPECTORS OF MIDWIVES
Authors: H. T. Sells
Journal: BMJ (1906)

Sympathetic paragangliomas are rare neuroendocrine tumours that arise from chromaffin cells and secrete catecholamines. On rare occasions, patients with sympathetic paragangliomas can present with symptoms of congestive heart failure. The optimal treatment is surgical to remove all disease and thereby improve survival as well as restore cardiac function. We report a case of a patient with a regional metastatic bladder paraganglioma and a succinate dehydrogenase complex subunit B gene mutation presenting with cardiomyopathy who had significant improvement in his cardiac function with surgical resection despite further progression of metastatic disease. During his 4-year follow-up period, the patient remains free from heart-failure signs and symptoms.
THE "L.E. CELL" AND ITS SIGNIFICANCE
Authors: PETER A. J. SMITH
Journal: British Journal of Dermatology (1952)

Journal Article THE “L.E. CELL” AND ITS SIGNIFICANCE Get access PETER A. J. SMITH, M.B., M.R.C.P. PETER A. J. SMITH, M.B., M.R.C.P. Division of Dermatology, University of Minnesota Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 64, Issue 1, 1 January 1952, Pages 10–25, https://doi.org/10.1111/j.1365-2133.1952.tb16156.x Published: 01 January 1952
Abstract P1-01-29: Clinical and Histopathological Factors Affecting Failed Sentinel Node Localization in Axillary Staging for Breast Cancer
Authors: M Dordea, H Colvin, A Pujol Nicolas, T Oshodi, O. Iwuchukwu
Journal: Cancer Research (2010)

Abstract Background: Sentinel lymph node biopsy (SLNB) has become the standard of care in axillary staging of clinically node-negative breast cancer patients. We hypothesize that clinical parameters are associated with failure to identify an axillary sentinel lymph node. Methods: We performed a retrospective review of 164 consecutive breast cancer patients who underwent SLNB from March 2008 to January 2010. A superficial injection technique was used as advocated by the UK National Training Programme (NEW START). All patients had lymphoscintigrams. Delayed imaging was performed if initial lymphoscintigram was negative up to 22 hours post-injection. Patient/surgical data, histopathological data and tumour location data were recorded. A univariate and multivariate analysis was performed. Results: Mean time from radiocolloid injection to surgery was 785.10 minutes (SD 435.97). 9/164 patients failed to show nodes on delayed imaging. In 2/9 patients successful SLNB was carried out following subareolar blue dye injection and 5 minute massage. 6/9 patients showed no evidence of radioactivity or blue dye. These patients underwent a stage 2 axillary clearance. 5/6 had multiple node involvement. Age and nodal status were significant factors (P&amp;lt;0.05). For every unit increase in age there was a 9% (CI, 0.84 - 0.99) reduced chance of failed sentinel node localization. Patients with negative nodal status had a 90% (CI, 0.02 - 0.99) reduced risk of failed sentinel node localization than patients with nodal macrometastasis and extracapsular nodal invasion. Weight (p=0.063, CI 0.91 - 1.03), previous breast surgery (p=0.062, CI 0.006 - 1.136) and tumour location (p=0.402, CI 0.03 - 4.17) showed weak association but failed to reach statistical significance. Discussion: Our results suggest that aberrant lymphatic flow secondary to tumour burden increase the chance of failed axillary sentinel node localization. Review of lymphoscintigrams showed that in all failed localizations the radiocolloid persisted around the injection site, showing limited local diffusion only. Similar findings were observed for blue dye injection. We further hypothesize that technical factors at the time of the injection may also play a role. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-29.
Thermal Burns in Diabetes Mellitus
Authors: Howard F. Root
Journal: New England Journal of Medicine (1945)

THE recent report of Taylor, Levenson and Adams1 emphasizes the marked hyperglycemia found in nondiabetic patients suffering severe thermal burns that involve 2 to 75 per cent of the body surface. Death occurred in 14 of their 35 cases. It is instructive to compare the metabolic changes when serious burns occur in diabetic patients in whom there is a known deficiency in insulin. For this reason, the following cases are reported to illustrate the effects of burns from hot water and from the sun's rays.Case 1 (4541). A 66-year-old housewife had diabetes of 7 years' duration. A leg had . . .
SURGICAL ANESTHESIA, WITH SPECIAL REFERENCE TO POSTANESTHETIC NAUSEA AND VOMITING.
Authors: W. TURNOR WOOTTON
Journal: JAMA (1907)

Much has been said and written on the important subject of anesthesia. Still there has been one particular point that has as yet never been satisfactorily settled, so far as I am able to learn. I refer to the distressing nausea and vomiting that so often follows the administration of ether and chloroform. After having exhausted such methods as lavage, filling the stomach with water prior to the operation, pungent odors to nostrils, hypodermic medication, etc., without any apparent beneficial result, I began experimenting with a measure at once simple in use, logical, harmless and, to my mind, expedient. We know that vomiting may be caused by a drug irritating the vomiting center directly, by being conveyed to it by the circulation or irritating it reflexly from the stomach when conveyed there by the circulation. Also that substances may be ingested which are irritating to the mucous membrane of the
Diphosphopyridine Nucleotide in the Treatment of Schizophrenia
Authors: Nathan S. Kline
Journal: JAMA (1967)

On the spring of last year, diphosphopyridine nucleotide (DPN or NAD, coenzyme I of the cellular oxidation-reduction systems) was claimed to be effective in short-term treatment of schizophrenia.<sup>1</sup>This method of treatment was based on the results of studies showing the purported beneficial effect of long-term administration of niacin (nicotinic acid, a constituent of the vitamin B complex) or its derivative niacinamide in schizophrenia.<sup>2,3</sup>Since niacinamide is an integral part of the coenzyme, it was suggested that these therapeutic effects were exerted by diphosphopyridine nucleotide and could readily be elicited by administering 1 to 2 gm of this preparation orally; 75% of the treated cases were said to show undeniable improvement five to seven days after the beginning of treatment.<sup>1</sup> Our evaluation of diphosphopyridine for the treatment of patients with chronic schizophrenia who were residing in our research ward will be reported in full in a speciality
Vermont moves closer to single payer healthcare financing
Authors: B. Roehr
Journal: BMJ (2011)

A one year study of the efficacy of the antifungal agent ketoconazole in non-invasive pulmonary aspergillosis was carried out. Ten patients, seven with allergic bronchopulmonary aspergillosis and three with mycetoma, were studied. They were randomly allocated to receive 400 mg daily or placebo orally in a double blind fashion. In the treated group (n = 6), concentrations of serum IgG specific for Aspergillus fumigatus fell significantly during treatment (mean reduction 42% (SEM 2.2%) compared with determinations preceding the study). This effect was evident by three months and continued for the 12 months of treatment. Patients receiving placebo (n = 4) showed no significant change in serum IgG concentration (mean change + 10% (SEM 5.3%]. Asthmatic patients treated with ketoconazole (n = 4) had significantly lower symptom scores than those receiving placebo (n = 3) (+0.45%/month (SEM 6.9%) versus +27%/month (SEM 6.5%); p less than 0.001). None of the patients treated with ketoconazole reported any adverse effects. Ketoconazole may cause serious liver damage but its use may be justified in bronchopulmonary aspergillosis if further experience confirms its ability to alter the course of a potentially serious disease.
Contrary to Guidelines, Teens Prescribed Opioids for Headache
Authors: Anita Slomski
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influence of immunosuppressive therapy in the incidence of chronic renal failure after liver transplantation
Authors: J.M. Moreno, A. Herreros, E. Rubino, J. Lopez, A. Gomez, V. Sanchez-Turrion, J. Revilla, E. Navarrete, Y. Gonzalez, V. Cuervas-Mons
Journal: Journal of Hepatology (2003)